Drug Detail

Information about Gleevec

Generic Name	Imatinib + Perifosine
IND	STI571 + KRX-0401
Brand Name (US)	Gleevec
Manufacturer	Novartis + Keryx
Drug Type	Tyrosine Kinase Inhibitor
Delivery	Oral
Approval Status	Gleevec is approved for GIST. This combination was evaluated in a phase 2 trial for GIST.
Indications
Overall Strategy	KIT Protein Based + Oncogenic Signal Path Based
Strategy	Block KIT + Block KIT Signal Path
Drug Category	KIT/PDGFRA inhibitor + AKT inhibitor

Imatinib (Gleevec) is the approved first line drug for GIST. Even in resistant GIST, it is believed that imatinib may provide control of some tumors and/or partial control of other tumors.
Perifosine is an oral inhibitor of the AKT protein. This protein is downstream in the KIT pathway. It is hoped that inhibition of AKT will provide additional antitumor effects compared to KIT inhibition alone.